Back to Search
Start Over
Pembrolizumab plus vorinostat is highly active in Hodgkin lymphoma, including cases refractory to prior PD-1 blockade
- Source :
- Blood; 20230101, Issue: Preprints
- Publication Year :
- 2023
-
Abstract
- •Pembrolizumab and vorinostat is well tolerated with a high ORR in RR cHL, with toxicities consistent with the known safety profiles of the 2 agents.•Pembrolizumab and vorinostat is active in RR cHL that is refractory to PD-1 blockade with an ORR of 56% in this subset.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs63384694
- Full Text :
- https://doi.org/10.1182/blood.2023020485